References
- 1. M. Peng, Y. Huang, T. Tao, C. Y. Peng, Q. Su, W. Xu, K. O. Darko, X. Tao and X. Yang, Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk, Sci. Rep. 6 (2016) 28611; https://doi.org/10.1038/srep28611
- 2. R. Arantes-Rodrigues, R. Pinto-Leite, L. Fidalgo-Gonçalves, C. Palmeira, L. Santos, A. Colaço and P. Oliveira, Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines, Biomed. Res. Int. (2013) 791406; https://doi.org/10.1155/2013/791406
- 3. E. W. Gerharz, A. Månsson and W. Månsson, Quality of life in patients with bladder cancer, Urol. Oncol.23 (2005) 201–207; https://doi.org/10.1016/j.urolonc.2005.03.005
- 4. E. J. Hillmer, H. Zhang, H. S. Li and S. S. Watowich, STAT3 signaling in immunity, Cytokine Growth Factor Rev.31 (2016) 1–15; https://doi.org/10.1016/j.cytogfr.2016.05.001
- 5. S. Bhattacharya, R. M. Ray and L. R. Johnson, STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells, Biochem. J. 392 (2005) 335–344; https://doi.org/10.1042/BJ20050465
- 6. J. Bromberg and J. E. Jr. Darnell, The role of STATs in transcriptional control and their impact on cellular function, Oncogene19 (2000) 2468–2473; https://doi.org/10.1038/sj.onc.1203476
- 7. M. Degoricija, M. Situm, J. Korać, A. Miljković, K. Matić, M. Paradžik, I. Marinović Terzić, A. Jerončić, S. Tomić and J. Terzić, High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study, World. J. Urol. 32 (2014) 1469–1475; https://doi.org/10.1007/s00345-014-1237-1
- 8. B. Zhang, Z. Lu, Y. Hou, J. Hu and C. Wang, The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells, Tumour Biol.35 (2014) 5401–5407; https://doi.org/10.1007/s13277-014-1704-8
- 9. H. H. Yeh, R. Giri, T. Y. Chang, C. Y. Chou, W. C. Su and H. S. Liu, Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell, DNA. Cell. Biol.28 (2009) 131–139; https://doi.org/10.1089/dna.2008.0762
- 10. R. J. Chen, Y. S. Ho, H. R. Guo and Y. J. Wang, Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta- adrenoceptors in human bladder cancer cells, Toxicol. Sci.115 (2010) 118–130; https://doi.org/10.1093/toxsci/kfq028
- 11. S. Parker, B. May, C. Zhang, A. L. Zhang, C. Lu and C. C. Xue, A pharmacological review of bioactive constituents of Paeonia lactiflora Pallas and Paeonia veitchii Lynch, Phytother. Res.30 (2016) 1445–1473; https://doi.org/10.1002/ptr.5653
- 12. J. Hao, X. Yang, X. L. Ding, L. M. Guo, C. H. Zhu, W. Ji, T. Zhou and X. Z. Wu, Paeoniflorin potentiates the inhibitory effects of erlotinib in pancreatic cancer cell lines by reducing ErbB3 phosphorylation, Sci. Rep.6 (2016) 32809; https://doi.org/10.1038/srep32809
- 13. X. H. Nie, J. Ou-yang, Y. Xing, D. Y. Li, X. Y. Dong, R. E. Liu and R. X. Xu, Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway, Drug. Des. Devel. Ther.9 (2015) 5611–5622; https://doi.org/10.2147/DDDT.S93912
- 14. H. Wang, H. Zhou, C. X. Wang, Y. S. Li, H. Y. Xie, J. D. Luo and Y. Zhou, Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo, Food Chem. Toxicol.50 (2012) 1560–1567; https://doi.org/10.1016/j.fct.2012.01.035
- 15. Y. B. Zheng, G. C. Xiao, S. L. Tong, Y. Ding, Q. S. Wang, S. B. Li and Z. N. Hao, Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling, World J. Gastroenterol.21 (2015) 7197–7207; https://doi.org/10.3748/wjg.v21.i23.7197
- 16. M. Y. Lin, S. Y. Chiang, Y. Z. Li, M. F. Chen, Y. S. Chen, J. Y. Wu and Y. W. Liu, Anti-tumor effect of Radix Paeoniae rubra extract on mice bladder tumors using intravesical therapy, Oncol. Lett.12 (2016) 904–910; https://doi.org/10.3892/ol.2016.4698
- 17. J. Liang, F. Xu, Y. Z. Zhang., S. Huang, X. Y. Zang, X. Zhao, L. Zhang, M. Y. Shang, D. H. Yang, X. Wang and S. Q. Cai, The profiling and identification of the absorbed constituents and metabolites of Paeoniae radix rubra decoction in rat plasma and urine by the HPLC-DAD-ESI-IT-TOF-MS(n) technique: a novel strategy for the systematic screening and identification of absorbed constituents and metabolites from traditional Chinese medicines, J. Pharm. Biomed. Anal.83 (2013) 108–121; https://doi.org/10.1016/j.jpba.2013.04.029
- 18. H. Wu, W. Li, T. Wang, Y. Shu and P. Liu, Paeoniflorin suppress NF-kappaB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells, Biomed. Pharmacother.62 (2008) 659–666; https://doi.org/10.1016/j.biopha.2008.08.002
- 19. S. Fang, W. Zhu, Y. Zhang, Y. Shu and P. Liu, Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation, Mol. Med. Rep.5 (2012) 351–356; https://doi.org/10.3892/mmr.2011.652
- 20. H. Wang, H. Zhou, C. X. Wang, Y. S. Li, H. Y. Xie, J. D. Luo and Y. Zhou, Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo, Food. Chem. Toxicol.50 (2012) 1560–1567; https://doi.org/10.1016/j.fct.2012.01.035
- 21. Z. D. Ge, A. W. Zhou, B. Wang, Y. X. Shen, C. H. Ding, A. P. Zhang, W. Wei and S. Y. Xu, Immunoregulatory effects of total glucosides of Paeony (TGP), Paeoniflorin (PF) and TGP removed PF on adjuvant arthritic rats, Chin. Pharmacol. Bull. 11 (1995) 303–305; https://doi.org/10.3321/j.issn:1001-1978.1995.04.012
- 22. Y. L. Zhu, L. Y. Wang, J. X. Wang, C. Wang, C. L. Wang, D. P. Zhao, Z. C. Wang and J. J. Zhang, Protective effects of paeoniflorin and albiflorin on chemotherapy-induced myelosuppression in mice, Chin. J. Nat. Med.14 (2016) 599–606; https://doi.org/10.1016/S1875-5364(16)30070-X
- 23. S. Goldar, M. S. Khaniani, S. M. Derakhshan and B. Baradaran, Molecular mechanisms of apoptosis and roles in cancer development and treatment, Asian Pac. J. Cancer. Prev.16 (2015) 2129–2144; https://doi.org/10.7314/APJCP.2015.16.6.2129
- 24. Z. Jin and W. S. El-Deiry, Overview of cell death signaling pathways, Cancer Biol. Ther.4 (2005) 139–163; https://doi.org/10.4161/cbt.4.2.1508
- 25. S. Wang and W. Liu, Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA-29b and matrix metalloproteinase-2, Mol. Med. Rep.14 (2016) 2143–2149; https://doi.org/10.3892/mmr.2016.5498
- 26. N. Yang, H. Cui, F. Han, L. Zhang, T. Huang, Y. Zhou and J. Zhou, Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP-9 and ERK signaling, Oncol. Lett.12 (2016) 1471–1476; https://doi.org/10.3892/ol.2016.4761
- 27. Z. Zhou, S. Wang, C. Song and Z. Hu, Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells, Onco. Targets Ther.9 (2016) 2511–2518; https://doi.org/10.2147/OTT.S102422
- 28. S. Hu, W. Sun, W. Wei, D. Wang, J. Jin, J. Wu, J. Chen, H. Wu and Q. Wang, Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis, Anticancer Drugs.24 (2013) 140–149; https://doi.org/10.1097/CAD.0b013e32835a4dac
- 29. H. Yu and R. Jove, The STATs of cancer--new molecular targets come of age, Nat. Rev. Cancer.4 (2004) 97–105; https://doi.org/10.1038/nrc1275
- 30. P. K. Epling-Burnette, J. H. Liu, R. Catlett-Falcone, J. Turkson, M. Oshiro, R. Kothapalli, Y. Li, J. M. Wang, H. F.Yang-Yen, J. Karras, R. Jove and T. P. Jr. Loughran, Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression, J. Clin. Invest.107 (2001) 351–362; https://doi.org/10.1172/JCI9940